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OBJECTIVES We evaluated the long-term outcome of patients with coronary artery disease and unexplained
syncope who were treated with an electrophysiologic (EP)-guided approach.
BACKGROUND Electrophysiologic studies are frequently performed to evaluate unexplained syncope in
patients with coronary artery disease. Patients with this profile who have inducible ventricular
tachycardia are considered at high risk for sudden death and increased overall mortality, and
therefore are often treated with an implantable cardioverter-defibrillator (ICD). The impact
of this EP-guided strategy is unknown because there are no data comparing the long-term
outcome of ICD recipients with that of noninducible patients.
METHODS We evaluated 67 consecutive patients with coronary artery disease and unexplained syncope.
All patients were treated with an EP-guided approach that included ICD implantation in
patients with inducible ventricular tachycardia.
RESULTS Electrophysiologic testing suggested a plausible diagnosis in 32 (48%) of these patients.
Inducible monomorphic ventricular tachycardia was the most common abnormality. Despite
frequent appropriate therapy with ICDs, the total mortality for patients with inducible
monomorphic ventricular tachycardia was significantly higher than for noninducible patients.
The respective one- and two-year survival rates were 94% and 84% in noninducible patients
and 77% and 45% in inducible patients (p 5 0.02).
CONCLUSIONS Electrophysiologic testing suggests an etiology for unexplained syncope in approximately 50%
of patients and risk stratifies these patients with regard to long-term outcome. Patients who
receive an ICD for the management of inducible ventricular tachycardia have a high incidence
of spontaneous ventricular arrhythmias requiring ICD therapy. However, despite ICD
implantation and frequent appropriate delivery of ICD therapies, patients with inducible
ventricular tachycardia have a significantly worse prognosis than do those who are nonin-
ducible. (J Am Coll Cardiol 1999;34:1082–9) © 1999 by the American College of
Cardiology
Electrophysiologic (EP) studies are frequently performed to
identify an arrhythmic cause for unexplained syncope (1–
12). Potential etiologies detected by EP testing include
sinus node or His-Purkinje system dysfunction as well as
sustained atrial or ventricular tachyarrhythmias. The great-
est positive yield has been reported in patients with under-
lying structural heart disease (2,4,7–9,11,12).
Because patients with syncope and inducible ventricular
tachycardia have an increased risk of sudden death as well
as total mortality (4,11,13), implantable cardioverter-
defibrillators (ICDs) are often implanted in these patients,
despite absence of a clinically documented sustained ven-
tricular arrhythmia. Follow-up of these patients has revealed
a high incidence of spontaneous ventricular tachycardia
requiring ICD therapy, suggesting that ICDs are efficacious
in the management of these patients (14–17).
See page 1096
However, despite the purported utility of an EP-guided
management strategy, several fundamental concerns limit
interpretation of the available data. Specifically, prior studies
have included a heterogeneous patient population with
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regard to cardiac diagnosis and have often included poten-
tially nonspecific findings such as the induction of nonsus-
tained ventricular tachycardia and ventricular fibrillation as
positive study end points (2,5,8,13). In addition, the long-
term follow-up of patients after EP testing has been
confounded by the concurrent use of empiric antiarrhythmic
drugs. Finally, the relative impact of ICD implantation in
inducible patients is unknown because the follow-up of
comparable noninducible patients has not been reported.
In this study we evaluated a homogeneous patient pop-
ulation with documented coronary artery disease and unex-
plained syncope. All patients were treated with an EP-
guided approach, which included ICD implantation in
patients with inducible ventricular tachycardia. The specific
purposes of this study were 1) to evaluate the results of EP
testing in these patients, 2) to compare the long-term
outcome of inducible and noninducible patients and 3) to
track the natural history of ICD recipients.
METHODS
Study population. We evaluated 100 consecutive patients
with structural heart disease and unexplained syncope who
underwent an EP study between January 1994 and Decem-
ber 1997. We excluded 33 patients without coronary artery
disease from further analysis. These included 20 patients
with a nonischemic dilated cardiomyopathy, 3 patients with
hypertrophic cardiomyopathy, 4 patients with a valvular
cardiomyopathy and 6 patients with congenital heart dis-
ease. Patients with a documented sustained ventricular
arrhythmia or those resuscitated from sudden cardiac death
were also excluded.
All patients underwent an extensive evaluation including
a history and physical examination, routine blood tests,
12-lead electrocardiography (ECG) and 24 h of in-patient
telemetry or ambulatory ECG monitoring. In all patients,
left ventricular (LV) ejection fraction was assessed by an
echocardiogram, radionuclide ventriculography or LV
cineangiography, and coronary artery disease was assessed
by stress testing with nuclear perfusion imaging or cardiac
catheterization. Patients with a negative EP study were
advised to undergo tilt testing, which was performed ac-
cording to our previously published protocol (18).
EP study. After written informed consent was obtained, all
patients underwent an EP study in the postabsorptive state.
No patient was on an antiarrhythmic drug at the time of
clinical presentation or the EP study.
Patients were locally anesthetized with 0.25% bupiv-
acaine and lightly sedated with midazolam or morphine.
Under fluoroscopic guidance, three 5F or 6F quadripolar
catheters with 5-mm interelectrode spacing (Bard EP [Bil-
lerica, Massachusetts], Daig, Minnetonka, Minnesota) were
advanced to the high right atrium, across the tricuspid valve
to record a His-bundle potential and to the right ventricular
apex or outflow tract. Bipolar intracardiac electrograms were
filtered at 30 to 500 Hz and displayed on a digital monitor.
Data were recorded on magnetic tape or optical disk (Prucka
Engineering, Houston, Texas). Programmed stimulation
was performed with an isolated current source (Bloom
Associates, Reading, Pennsylvania), and stimuli were deliv-
ered as rectangular pulses of 2-ms duration at 4 times the
diastolic threshold.
Sinus node dysfunction was evaluated by the corrected
sinus node recovery time (at basic drive cycle lengths of 600,
500, and 400 milliseconds [ms]) and sinoatrial conduction
time. Incremental atrial pacing was performed until atrio-
ventricular (AV) nodal Wenckebach was reached. Atrial
extrastimuli were delivered for the evaluation of dual AV
nodal physiology and sustained atrial arrhythmias. Pro-
grammed ventricular stimulation included up to triple ven-
tricular extrastimuli at two cycle lengths from two right
ventricular sites. Patients with a negative baseline study
received isoproterenol (1 to 5 mg/min titrated to increase
heart rate by $20% over baseline), and the study was
repeated from up to two right ventricular sites. Patients with
inducible monomorphic ventricular tachycardia received
intravenous (IV) procainamide (1000 to 1500 mg bolus
followed by a continuous infusion of 4 to 8 mg/min) and
underwent a repeat EP study according to the same proto-
col. No patient underwent stimulation from the LV. Sus-
tained monomorphic ventricular tachycardia was the only
positive end point of ventricular stimulation.
Definitions. Coronary artery disease was defined as 1)
$50% reduction in luminal diameter of at least one of the
three major epicardial coronary arteries, 2) a documented
myocardial infarction or 3) a perfusion abnormality on
nuclear imaging in $1 coronary artery territory. Sinus node
dysfunction was defined as a corrected sinus node recovery
time $550 ms or a sinoatrial conduction time of $125 ms.
Significant His-Purkinje system dysfunction was defined as 1)
a HV interval of $100 ms at baseline or after IV procain-
amide or 2) the development of infra-Hisian block with
rapid atrial pacing at a cycle length of $400 ms. Sustained
monomorphic ventricular tachycardia was defined as mono-
morphic ventricular tachycardia, regardless of cycle length,
lasting $30 s or requiring termination due to hemodynamic
compromise. Deaths were classified as cardiac, noncardiac
or unknown based on the assessment of the referring
Abbreviations and Acronyms
AV 5 atrioventricular
CABG 5 coronary artery bypass grafting
ECG 5 electrocardiogram, electrocardiography
EP 5 electrophysiology, electrophysiologic
ICD 5 implantable cardioverter-defibrillator
IV 5 intravenous
LV 5 left ventricle, left ventricular
PTCA 5 percutaneous transluminal coronary
angioplasty
1083JACC Vol. 34, No. 4, 1999 Mittal et al.
October 1999:1082–9 EP-Guided Management of Syncope
physicians. Sudden death was defined as death occurring
while the patient was asleep or within 1 h of the onset of
symptoms.
Therapy. Patients with inducible monomorphic ventricular
tachycardia who were suppressed with IV procainamide
underwent EP-guided serial antiarrhythmic drug trials.
Patients who remained inducible despite IV procainamide
received a tiered therapy ICD. Noninducible patients with
isolated sinus node or His-Purkinje system dysfunction
received a dual chamber pacemaker. Patients with a positive
tilt-table test were treated with a beta-adrenergic blocking
agent or pacemaker. No patient received empiric antiar-
rhythmic drug or device therapy upon hospital discharge.
Follow-up. Patients with an ICD or pacemaker were
followed in our arrhythmia clinic every three to six months.
Stored electrograms were retrieved from ICD recipients.
Patients not receiving a device were evaluated by telephone
follow-up. Information was obtained regarding initiation of
new antiarrhythmic drugs, recurrence of syncope or the
identification of an alternative etiology for syncope by
patients’ referring physicians.
Statistical analysis. All continuous variables are expressed
as mean 6 standard deviation. Comparisons of inducible
and noninducible patients were made using the chi-square
or Fisher exact test (for categorical variables) and the
Student t test for independent samples (for continuous
variables). Kaplan-Meier survival curves were generated for
1) ventricular tachycardia/fibrillation-free survival in pa-
tients with inducible ventricular tachycardia who received an
ICD and 2) total mortality between inducible and nonin-
ducible patients. Comparisons between survival curves were
made using the log-rank statistic. A univariate Cox
proportional-hazards regression model was employed to
evaluate the effect of age, gender, number of syncopal
episodes, history of myocardial infarction, history of non-
sustained ventricular tachycardia, LV ejection fraction, pres-
ence of bundle-branch block, baseline (HV) interval, induc-
ibility of monomorphic ventricular tachycardia and cycle
length of induced tachycardia on mortality. A p value of
,0.05 was considered statistically significant.
RESULTS
The study population consisted of 67 patients (57 male, 10
female) with documented coronary artery disease and unex-
plained syncope. The mean LV ejection fraction was 37 6
13%. A history of myocardial infarction was present in 42
(63%) patients. Baseline demographics are outlined in
Table 1.
Noninvasive evaluation. On baseline ECG, the rhythm
was sinus in 58 (87%) patients, atrial fibrillation or flutter in
8 (12%) patients and paced in 1 (1%) patient. First-degree
AV delay was present in 9 (13%) patients. Bundle branch
block was present in 24 (36%) patients and included a
left-bundle branch block in 7 patients, right-bundle branch
block in 3 patients, right-bundle branch block with a left
anterior or posterior fascicular block in 9 patients and a
nonspecific intraventricular conduction delay in 5 patients.
Other findings included LV hypertrophy in 2 (3%) patients
and pathologic Q waves in 25 (37%) patients.
Nonsustained ventricular tachycardia (9 6 4 beats) was
documented in 31 (46%) patients. The shortest cycle length
during nonsustained ventricular tachycardia was 395 6
46 ms. A signal-averaged ECG was performed in 26
patients, without underlying bundle branch block, and was
abnormal (as previously defined [19]) in 15 (58%) of these
patients.
Evaluation of coronary artery disease. Cardiac catheter-
ization was performed in 50 (75%) patients. Of these 50
patients, 11 (22%) had single-vessel, 11 (22%) had double-
vessel and 28 (56%) had triple-vessel coronary artery disease.
In addition, 10 (15%) patients had a LV aneurysm. A
diagnosis of coronary artery disease was made on the basis of
nuclear stress imaging in the remaining 17 (25%) patients.
Eleven (16%) patients had previously undergone percu-
taneous transluminal coronary angioplasty (PTCA) and 37
(55%) had previously undergone coronary artery bypass
grafting (CABG). Of the 37 patients with a history of
CABG at the time of the EP study, 9 had undergone
surgery during the same hospitalization. These patients
presented with syncope and were discovered upon evalua-
tion to have coronary artery disease requiring CABG prior
to EP study.
EP study. The baseline HV interval was 56 6 13 ms. Only
one patient (HV 5 100 ms) had severe His-Purkinje system
dysfunction. Of the 58 patients in sinus rhythm, 7 patients
had sinus node dysfunction. In addition, 10 of these 58
patients had dual AV nodal physiology but none had
Table 1. Baseline Demographics
No. of patients 67
Gender
Male 57
Female 10
Age (yr) 70 6 10
LV ejection fraction (%) 37 6 13
Prior myocardial infarction 42 (63%)
Episodes of syncope
1 47 (70%)
2 12 (18%)
$3 8 (12%)
Medications
ACE-inhibitors 33 (49%)
Aspirin 49 (73%)
Beta-blockers 29 (43%)
Calcium-blockers 10 (15%)
Digoxin 24 (36%)
Diuretics 23 (34%)
Nitrates 27 (40%)
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inducible AV nodal reentrant tachycardia. Table 2 depicts
the characteristics of patients with a positive EP study.
Sustained monomorphic ventricular tachycardia was in-
ducible in 29 (43%) patients. The cycle length of induced
ventricular tachycardia was 248 6 37 ms; 15 (52%) patients
had an induced ventricular tachycardia cycle length of
#250 ms. All patients required either double or triple
ventricular extrastimuli for induction of ventricular tachy-
cardia. No patient required isoproterenol for induction of
tachycardia. Four of the seven patients with sinus node
dysfunction had concomitant inducible ventricular tachycar-
dia, as did the one patient with severe His-Purkinje system
dysfunction.
In an additional 11 patients, sustained ventricular fibril-
lation was the only induced ventricular tachyarrhythmia.
Ventricular fibrillation was induced with double ventricular
extrastimuli in one patient and with triple ventricular
extrastimuli in the remainder. These 11 patients were
considered to have a negative EP study.
Patients with inducible monomorphic ventricular tachy-
cardia had greater LV dysfunction, greater likelihood of a
prior myocardial infarction, and a longer baseline HV
interval (Table 3). However, inducibility could not be
predicted by other baseline demographic variables including
age, gender, number of syncopal episodes, presence of
bundle-branch block or nonsustained ventricular tachycar-
dia or severity of coronary artery disease, including the
presence of an LV aneurysm or history of prior revascular-
ization with PTCA or CABG.
Procainamide was administered to 25 of the 29 patients
with inducible monomorphic ventricular tachycardia. Of the
four patients who did not receive procainamide, two had
severe LV dysfunction with concomitant congestive heart
failure and two others had moderate-severe His-Purkinje
system dysfunction (HV interval of 79 and 90 ms). Ven-
tricular tachycardia was suppressed following an infusion of
procainamide in only one patient.
Therapy. POSITIVE EP STUDY. The single patient with in-
ducible monomorphic ventricular tachycardia that was sup-
pressible with IV procainamide was treated with amioda-
rone after a repeat EP study confirmed drug efficacy. Of the
remaining 28 patients with inducible monomorphic ventric-
ular tachycardia, 26 received an ICD. One patient refused
an ICD; the other patient died of ventricular fibrillation,
which developed from sustained monomorphic ventricular
tachycardia, on the fifth day post-EP study. This patient
was awaiting resolution of PTCA-related acute renal insuf-
ficiency before receiving an ICD. Most ICDs (24/26) were
implanted using a nonthoracotomy approach and trans-
venous leads. Twenty-three of the 26 ICDs had the capacity
for stored electrogram retrieval. No mortality was associated
with ICD implantation. Three patients with isolated sinus
node dysfunction received a pacemaker.
NEGATIVE EP STUDY. Four of 35 patients with a negative
EP study received a pacemaker. Of these patients, one had
tachycardia-bradycardia syndrome, one had a 4-s episode of
AV block during atrial fibrillation and two patients had
neurally mediated syncope during tilt-table testing, which
did not respond to beta-blocker therapy. An additional two
patients with a negative EP study had a positive tilt test and
were treated with a beta-blocker. The remaining 29 (43%)
patients with a negative EP study were discharged without
the addition of any empiric therapy. Ten of these 29
patients also had a negative tilt test.
Clinical follow-up. Follow-up was available in 60 (90%)
patients at a mean of 448 6 387 days (maximum 1430
days). During the follow-up period, six patients had recur-
rent syncope. Two of these patients had received an ICD for
management of inducible ventricular tachycardia. In one
patient, recurrent syncope was associated with ventricular
fibrillation that was successfully defibrillated by the ICD.
The cause of syncope in the other patient was unknown.
Review of stored electrograms revealed no arrhythmia. The
remaining four patients had been noninducible at the initial
EP study. Two of these patients were later diagnosed with
hypoglycemia, one patient was diagnosed with a seizure
disorder and in another patient, the cause of syncope
remains unknown.
Eleven patients (41%) with an ICD received appropriate
therapy for sustained ventricular tachycardia (9 patients) or
ventricular fibrillation (2 patients) at 155 6 164 days (range:
1 to 522 days) post-ICD implantation. In the nine patients
with spontaneous ventricular tachycardia, the cycle length of
tachycardia was 293 6 40 ms.
An antiarrhythmic drug was initiated in five patients
during follow-up period. This included amiodarone in two
patients, sotalol in two patients and azimilide in one patient.
The indication for initiation of an antiarrhythmic drug was
atrial fibrillation (leading to an inappropriate ICD dis-
charge) in two patients and an appropriate ICD discharge
for ventricular tachycardia in three patients.
Fifteen patients died during the follow-up period at a
mean of 350 6 287 days (range 5 to 960 days). Nine of these
patients had inducible monomorphic ventricular tachycardia
at the initial EP study, whereas six patients were noninduc-
ible. Table 4 summarizes the mortality data for patients with
available follow-up.
Of the five patients with a cardiac cause of death, two had
sudden death without a documented arrhythmia. In addi-
tion, death due to recurrent documented ventricular tachy-
cardia/fibrillation was observed in three patients. These
included the patient who died awaiting an ICD implant, a
patient who presented with an acute myocardial infarction
and had recurrent ventricular tachyarrhythmias and a pa-
tient who had a protracted hospital course for multisystem
organ failure. In the latter two patients, the ICD converted
ventricular fibrillation to a supraventricular rhythm; how-
ever, both patients died of resulting electromechanical
dissociation. Overall, four of the five deaths due to a
presumed cardiac cause occurred in inducible patients; in
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contrast, five of the eight noncardiac deaths occurred in
noninducible patients. Of the 11 patients in whom ventric-
ular fibrillation was the only induced arrhythmia at EP
study, 2 died over the follow-up period. In both cases, death
was due to a noncardiac cause.
Survival without recurrent ventricular tachycardia or fi-
brillation was observed in only 47% and 21% of patients at
one and two years’ post-ICD implantation, respectively
(Fig. 1). Total mortality was significantly higher in patients
with inducible monomorphic ventricular tachycardia despite
therapy with an ICD (Fig. 2). The respective one- and
two-year survival rates were 94% and 84% in noninducible
patients and 77% and 45% in inducible patients (p 5 0.02).
Univariate Cox proportional-hazards regression modeling
identified inducibility of monomorphic ventricular tachycar-
dia as the only significant predictor of overall mortality (p 5
0.03). Of note, no difference in outcome was observed
between patients with an induced ventricular tachycardia
cycle length of #250 ms and .250 ms at initial EP study.
DISCUSSION
The principal findings of this study are that in patients with
coronary artery disease and unexplained syncope, EP testing
suggests a probable arrhythmogenic cause in approximately
50% of patients. By identifying those patients with inducible
monomorphic ventricular tachycardia, EP testing risk strat-
ifies patients into high- and low-risk groups with respect to
long-term cardiac and total mortality. In addition, patients
who receive an ICD for the management of inducible
ventricular tachycardia and unexplained syncope have a high
incidence of spontaneous ventricular arrhythmias requiring
ICD therapy. Most significantly, the results of this study
suggest that, despite frequent appropriate ICD therapy,
patients with inducible ventricular tachycardia are at high
risk of cardiac and total mortality, with a two-year survival
rate less than 50%.
Inducibility. Although our yield during EP testing was
similar to rates previously reported in patients with unex-
plained syncope and structural heart disease, we excluded
induction of nonsustained ventricular tachycardia and ven-
tricular fibrillation as positive study end points because these
findings may be nonspecific responses to the stimulation
Table 3. Comparison of Inducible and Noninducible Patients
Inducible
Patients
(n 5 29)
Noninducible
Patients
(n 5 38)
p
Value
Age 71 6 10 70 6 10 NS
Male 25 (86%) 32 (84%) NS
Episodes of syncope NS
1 24 (83%) 23 (61%)
2 3 (10%) 9 (24%)
$3 2 (7%) 6 (16%)
Prior myocardial infarction 22 (76%) 20 (53%) 0.05
LV ejection fraction (%) 32 6 11 41 6 12 0.003
History of nonsustained VT 13 (45%) 18 (47%) NS
Bundle-branch block 13 (45%) 11 (29%) NS
Baseline HV interval (ms) 60 6 15 52 6 10 0.009
Table 4. Mortality Data of Patients With Available Follow-up
Inducible Patients
(n 5 27)
Noninducible Patients
(n 5 33)
No. of deaths 9 6
Cause of death
Cardiac 4 1
Noncardiac 3 5
Unknown 2 0
Figure 1. Arrhythmia-free survival in ICD recipients. This
Kaplan-Meier curve demonstrates the likelihood of survival with-
out recurrent ventricular tachycardia or fibrillation in patients with
syncope receiving an ICD for the management of inducible
ventricular tachycardia. The numbers at the bottom represent the
number of patients at risk (N).
Figure 2. Comparison of survival between inducible and nonin-
ducible patients. This Kaplan-Meier curve compares the overall
survival for patients with (dashed line) and without (solid line)
inducible ventricular tachycardia at EP study. Despite therapy with
ICDs, inducible patients had a markedly worse long-term outcome
than did noninducible patients. The numbers at the bottom
represent the number of patients at risk. I: inducible group; NI:
noninducible group.
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protocol (19,20). Induction of these arrhythmias accounted
for approximately half the positive end points in prior
studies (2,5,8,13). In the present study, induction of ven-
tricular fibrillation failed to confer an increased mortality
risk.
Patients with inducible monomorphic ventricular tachy-
cardia had a markedly worse prognosis than did noninduc-
ible patients. Patients with a history of myocardial infarction
and depressed LV function were most likely to have
inducible ventricular tachycardia at EP study. However,
other baseline demographic variables failed to predict in-
ducibility. These findings demonstrate that inducibility of
sustained monomorphic ventricular tachycardia is a marker
of an extremely poor outcome in patients with ischemic
heart disease and unexplained syncope.
Effects of ICDs. Because patients with unexplained syn-
cope and inducible ventricular tachycardia have an increased
risk of sudden death and total mortality (4,11,13), it has
been suggested that ICD implantation is an effective man-
agement strategy in these patients (16,17). A high incidence
of appropriate ICD therapies, similar to that in patients
receiving ICDs for management of sustained ventricular
tachycardia or fibrillation, has been observed in these
patients and supports this approach (14,15). A similar
finding was observed in our study, which confirms the
potential utility of ICDs in the management of patients
with syncope and inducible ventricular tachycardia.
However, despite receiving ICDs, seven patients died
during the follow-up period. Unfortunately, in these pa-
tients, stored electrograms could not be retrieved. However,
in three of these patients, death was presumed to have a
cardiac etiology. Overall, despite the use of ICDs, the total
mortality of inducible patients remained significantly higher
than of noninducible patients. In this study, other risk
factors for mortality could not be identified. It is important
to note that the cycle length of induced ventricular tachy-
cardia did not differentiate patients with respect to outcome.
Therefore, in this patient cohort, induced sustained mono-
morphic ventricular tachycardia, regardless of cycle length,
can be considered to be prognostically significant.
Prior studies. In the two prior studies that evaluated the
utility of ICDs in patients with syncope and inducible
ventricular tachycardia (16,17), data were provided for only
a select group of inducible patients who received an ICD.
Neither study reported data on the follow-up of patients
with unexplained syncope who were either inducible and
not treated with an ICD or noninducible during EP study.
Link et al. (16) reported on 50 patients who received an
ICD after presenting with presyncope or syncope. Their
patients had an appropriate ICD discharge rate of 22% at
one year and 50% at three years’ post-ICD implantation.
Only four patients died during the follow-up period of 23 6
15 months. Their study differs from ours in several respects.
First, their patients represented a heterogeneous group with
differing underlying cardiac pathology, including patients
with nonischemic cardiomyopathy. Second, therapy was not
uniform as only 50 of the 82 inducible patients received an
ICD. In addition, the follow-up data of inducible patients
not receiving an ICD were not reported. Third, they
considered nonsustained ventricular tachycardia and ven-
tricular fibrillation as positive end points, which accounted
for approximately 30% of “inducible” patients. The speci-
ficity of these findings in patients without a documented
sustained arrhythmia is unknown. Finally, approximately
35% of the implanted ICDs lacked the capacity for stored
electrogram retrieval and approximately 35% of patients
were discharged with concomitant antiarrhythmic drug
therapy, factors that complicate interpretation of the natural
history in these patients.
Militianu et al. (17) reported on 33 patients who received
an ICD after presenting with syncope. These patients were
collected over a 10-year period from seven institutions. At
least one appropriate ICD discharge was observed in 36% of
patients over a follow-up period of 17 months. Similar to
the previous study, patients were nonuniform with respect
to cardiac diagnosis. Nearly one-half of patients receiving an
ICD were inducible for only ventricular flutter or fibrillation
or were noninducible. One-third of implanted ICDs lacked
the capacity for stored electrogram retrieval, and a history of
concomitant antiarrhythmic drug use was not reported.
Our study has several unique features. We evaluated only
patients with documented coronary artery disease to elimi-
nate the confounding contribution of differences in cardiac
pathology in determining the ultimate long-term outcome
in patients with unexplained syncope. We defined prespeci-
fied end points for a positive EP outcome. These end points
did not include a baseline HV interval ,100 ms or
induction of nonsustained ventricular tachycardia or ven-
tricular fibrillation because these may be nonspecific find-
ings (7,20). The treatment of patients was uniform. On the
basis of the results of the EP study, pacemakers were
implanted in patients with isolated sinus node dysfunction
and ICDs were implanted in patients with inducible mono-
morphic ventricular tachycardia that was not suppressible
with procainamide. No patient was subject to empiric drug
or device therapy. The implantation of ICDs with the
capacity for stored electrogram retrieval and the absence of
empiric therapy provide a unique opportunity to evaluate
the natural history of these patients. Finally, to our knowl-
edge, this is the first study to assess and contrast the
outcome of inducible patients treated with an ICD with
noninducible patients in a homogeneous cohort with unex-
plained syncope.
Study limitations. There are several limitations in this
study. Because all our patients had coronary artery disease,
the applicability of the data to patients with other forms of
structural heart disease and unexplained syncope is un-
known. Second, although inducible patients had a worse
outcome than did noninducible patients, despite implanta-
tion of an ICD, the magnitude of the potential benefit of an
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ICD in inducible patients could not be determined from
this study. To determine this benefit, patients with unex-
plained syncope and inducible ventricular tachycardia would
need to be randomized to receive an ICD or no therapy.
However, because important ethical issues could be raised if
ICD therapy were withheld from patients with coronary
artery disease, syncope and inducible ventricular tachycar-
dia, we considered it prudent to treat all inducible patients
with ICDs. Finally, although not readily accessible, the
outcome of patients with coronary artery disease and unex-
plained syncope who were admitted to our institution
during the course of this study but not referred for an EP
study would have been of interest.
Conclusions. Electrophysiologic testing is an effective di-
agnostic test in patients with coronary artery disease and
unexplained syncope. It provides an etiology for syncope in
approximately 50% of patients, and it risk-stratifies patients
with regard to long-term outcome. Patients who undergo
ICD implantation for management of inducible ventricular
tachycardia and unexplained syncope have a high incidence
of spontaneous ventricular arrhythmias requiring ICD ther-
apy. However, despite ICD implantation and appropriate
delivery of ICD therapies, patients with inducible ventric-
ular tachycardia have a significantly worse prognosis than do
noninducible patients, with a two-year survival rate less than
50%. These results suggest that ICD therapy alone may not
be sufficient for the management of inducible patients. In
this context, the prognostic significance of the remaining
ischemic burden, as well as other co-morbid diseases in
these patients, needs to be prospectively examined.
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